Replies to post #125022 on Biotech Values

[DewDiligence]

…if FCSC stays cash blow break even on the cosmetic front (which would probably only require a few thousand treatments of LaViv)…

laViv will never generate material profits, IMO.

A few weeks ago, I challenged posters to show how laViv could be cash-flow positive during the next five years (#msg-64658445). The only poster who replied to my query produced a model that assumed a 100% (!) gross margin (#msg-64658880). When I pointed out this error (#msg-64658880), the thread devolved into hopes and dreams rather than anything of substance (#msg-64660101).

To this date, I haven’t seen a credible calculation to show that laViv is anything but a loser product that caused the previous incarnation of FCSC to file for bankruptcy two years ago.